Innovations

DIAGNOSTICS & IMAGING

COVID LFA Platform

Learn MoreOrange Plus Sign

NEW TECHNOLOGIES

IN-SITU Oxygen Filling and Storage System

Learn MoreOrange Plus Sign

SENSORS & WEARABLES

Machine Learning for HPV and Cervical Cancer

Learn MoreOrange Plus Sign

Our Board and Leadership Team

  • Niranjan

    Bose

    Board Member

    Niranjan

    Bose

    Board Member

    Niranjan Bose serves as member of the Board of Directors at GH Labs. Currently, he is Managing Director for Health & Life Sciences Strategy at Gates Ventures LLC, where he also serves as Science Advisor to Bill Gates.

    Prior to joining Gates Ventures in 2014, he was the Chief of Staff to the President of the Global Health Program at the Bill & Melinda Gates Foundation. During his tenure there, he was responsible for managing a portfolio of vaccine investments focused on pediatric diarrheal and respiratory diseases. This work included leading the Foundation’s cholera and rotavirus vaccine strategies.

    Before that, Niranjan worked for the management consulting firm Strategic Decisions Group (and SDG Life Sciences), where his engagements with pharma and biotech clients drove strategy development, deal structuring, and portfolio management.

    Niranjan holds a Ph.D. in Biochemistry from Dartmouth College, an M.S. in Biological Sciences and a B.S. in Pharmaceutical Sciences from the Birla Institute of Technology and Science, in Pilani, India. He also holds a Business Bridge Diploma from the Tuck School of Business at Dartmouth.

  • Elisa

    Keller

    Board Member

    Elisa

    Keller

    Board Member

    Elisa Mandell Keller serves as member of the Board of Directors at GH Labs. Currently, she is the principal of EMK Strategic Consulting, a firm that provides strategic guidance and analysis to for-profit and nonprofit organizations.

    Previously, Elisa worked at the Bill & Melinda Gates Foundation, most recently as Director and Chief of Staff to the Foundation’s Chief Strategy Officer and President of Global Policy & Advocacy. She also served as Deputy Director for Strategy, Planning and Management for the Agricultural Development team and as was Chief of Staff to the president of the Gates Foundation’s Global Development Program.

    Before she joined the Foundation, Elisa was a consultant with PATH (Program for Appropriate Technology in Health), helping create a social equity fund to invest in health technologies relevant to the developing world. She has also worked as a high school teacher in the rural village of Oshikuku, Namibia, as well as for New York City Schools’ Chancellor Joel Klein. Elisa began her career at McKinsey & Company in Seattle, working on healthcare and biotechnology, retail, and U.S. and international education.

    Elisa holds a B.S. in Education and Social Policy with a focus on organizational development from Northwestern University.

  • Ankur

    Vora

    Board Member

    Ankur

    Vora

    Board Member

    Ankur Vora serves as member of the Board of Directors at GH Labs. Currently, he is Chief Strategy Officer of the Bill & Melinda Gates Foundation, where he serves as principal advisor to the co-chairs, chief executive officer, and Executive Leadership Team on the foundation’s overall strategic opportunities, risks, and tradeoffs. He leads the Strategy Office, which is responsible for enabling the highest and best use of the Foundation’s resources – co-chair time, reputation, people, and dollars – to accelerate the Foundation’s impact.

    Prior to joining the Foundation, Ankur was the director of programs at the Children’s Investment Fund Foundation (CIFF) in London, where he oversaw a cross-cutting portfolio of programs focused on health, nutrition, education, and climate change across Africa and South Asia.

    He has also served as principal at the Boston Consulting Group (BCG), where he focused on healthcare, financial services, and social impact projects. Before that, Ankur was a lecturer of Economics at the University of Chicago. He also worked briefly at Goldman Sachs, the Industrial Development Bank of India, and the Bhabha Atomic Research Center in India.

    Additionally, he serves on the Board of Directors at Innovations for Poverty Action.

    Ankur holds a Ph.D. in Economics from the University of Chicago, and an M.S. in Economics and B.S. in Computer Science from the Birla Institute of Technology and Science, in Pilani, India.

  • Steven

    Kern

    President & Interim CEO

    Steven

    Kern

    President & Interim CEO

    To the role of interim CEO of GH Labs, Steve Kern brings a passion for global health technology innovation and nearly 40 years of cross-sector experience in pharmacokinetic and pharmacodynamic modeling, clinical pharmacology, control systems engineering for drug delivery, and medical device development.

    Prior to GH Labs, Steve led the Quantitative Sciences Team at the Bill & Melinda Gates Foundation, providing quantitative analyses that shaped program strategies and therapeutic product development efforts in global health. Previously, Steve served as Global Head of Pharmacology Modeling at Novartis Pharma AG based in Basel, Switzerland, where his team provided model-based drug development support to therapeutics initiatives that spanned a range of disease conditions and all stages of product development. Before that, Steve was Associate Professor of Pharmaceutics, Anesthesiology, and Bioengineering at the University of Utah in Salt Lake City, where he also served as co-investigator for their NIH funded Pediatric Pharmacology Research Unit.

    Steve earned his PhD in Bioengineering from the University of Utah, MEng in Bioengineering from Penn State University, and BS in Mechanical Engineering from Cornell University.

  • Sharon

    Bergquist

    VP, STRATEGY & PLANNING

    Sharon

    Bergquist

    VP, STRATEGY & PLANNING

    As Vice President of Strategy and Planning at GH Labs, Sharon Bergquist is responsible for maintaining strong alignment between GH Labs and the Bill & Melinda Gates Foundation, including strategic alignment of project portfolios in tools and technologies for Primary Healthcare Centers (PHC), Maternal Newborn Child Health (MNCH), and Diagnostics (Dx), ensuring the development of high-quality project plans with clear articulation of critical decision points for implementation. She also oversees GH Labs steering committees and helps shape internal processes to ensure robust and effective collaboration with external partners.

    Previously, Sharon was a Director at Gates Ventures’ Health & Life Sciences team, where she managed a portfolio that includes the Seattle Flu Study/SCAN and Alzheimer’s Disease therapeutics investments. She also managed the Bill & Melinda Gates Foundation’s and GH Labs’ relationships on MNCH, Discovery and Translational Sciences, Vaccine Development and Surveillance, and Pneumonia, focusing largely on strategy reviews, learning agendas and research intersections.

    Prior to working at Gates Ventures, Sharon worked at the Bill & Melinda Gates Foundation, where she was most recently on Melinda Gates’ strategy team, after working on the MNCH Discovery and Tools team leading the neurodevelopment initiative.

    Sharon received her Ph.D. in Neuroscience from the University of California, San Francisco, and her B.S. in Biology from the University of California, San Diego.

  • Kera

    Dennis

    VP, Finance & Operations

    Kera

    Dennis

    VP, Finance & Operations

    As Vice President of Finance and Operations at GH Labs, Kera Dennis is responsible for Finance, IT, Facility Management, and Environmental Health & Safety.

    Prior to joining GH Labs, Kera served as Associate Administrator at Harborview Medical Center where she partnered with research, educational, and clinical teams to advance the campus facility master plan by providing operational support, facility management, and financial leadership including forecasting and analysis. She also developed the medical center’s budgeting and long-range financial and capital plans, working in conjunction with health system executive management, medical staff, and governing boards.

    Previously, Kera held roles at Oregon Health & Science University (OHSU) and Banner Health at the University of Arizona where she was responsible for financial reporting and business planning. She also co-chaired the Energy Task Force at OHSU to promote dependable, affordable, and environmentally sound energy use.

    Kera holds a Master’s in Business Administration from the Lundquist College of Business at the University of Oregon and a B.S. in Finance from the University of Arizona.

  • Davina

    Inslee

    VP, Legal

    Davina

    Inslee

    VP, Legal

    As Vice President of Legal at GH Labs, Davina Inslee oversees all legal matters, including contracts, technology transfer, tax planning, regulatory, corporate governance, and compliance.

    Prior to joining GH Labs, she was Counsel at the firm Davis Wright Tremaine. Her practice concentrated on the technology industry, including product development and commercialization, intellectual property licensing, compliance, and distribution.

    Before that, Davina was a Chief Counsel at Vulcan Inc. and Intellectual Ventures, where she supported development for diagnostics, machine learning, clean energy, and other transformative technologies with an emphasis in biotechnology. Her work led to product development for affordable and accessible technologies that solve the biggest problems in global health, such as malaria diagnostics, portable, smart ultrasound, HPV image recognition, medical cold-chain equipment, computational disease modeling, and rapid diagnostics.

    Davina holds a J.D. from Indiana University and a B.S. in Biological Sciences from Purdue University.

  • Rob

    Jenison

    VP, Research & Product Development

    Rob

    Jenison

    VP, Research & Product Development

    As Vice President of Research and Product Development at GH Labs, Rob Jenison oversees the translation of inventive technologies into products through commercial partnerships, to serve the needs of people in LMICs.

    Prior to joining GH Labs, Rob served as Vice President of Product Development and Commercialization Strategy at Global Good. Previously, he served as CTO/SVP R&D at Great Basin Scientific (now Vela Diagnostics) where he led the creation of a molecular diagnostic platform that resulted in six FDA-approved products. Before that, Rob led the development of a high-throughput genotyping platform at Thermo Biostar in collaboration with the Nichols Institute, Quest Diagnostics. Rob also developed RNA-based diagnostic and therapeutic agents at NeXstar Pharmaceuticals and Ionis Pharmaceuticals.

    Rob holds a B.S. in Chemistry/Biochemistry from the University of California, San Diego.

  • Daniel

    Lieberman

    Senior Director, Engineering & Software

    Daniel

    Lieberman

    Senior Director, Engineering & Software

    As Senior Director of Engineering and Software at GH Labs, Daniel Lieberman oversees the development of technologies to bridge gaps in primary healthcare.

    Before he joined GH Labs, Daniel managed a team at Exponent, an engineering consulting firm engaging in failure analysis and product design. He has also held part-time faculty positions at the University of Southern California and at École des Métiers de l’Aérospatiale de Montréal. An engineer by training, Daniel has more than 20 years of experience investigating thermo-fluid systems in a number of areas including cryogenics, respiratory systems, chemically reacting flows, and propulsion devices.

    Daniel holds a Ph.D. and M.S. in Aeronautics from the California Institute of Technology and a B.Eng. in engineering from McGill University.

  • Wei

    Luo

    Senior Director, Product Management

    Wei

    Luo

    Senior Director, Product Management

    As Senior Director of Product Management at GH Labs, Wei Luo leverages his extensive and diverse experience in technology innovation to drive end-to-end progress across the product development lifecycle.

    Previously, Wei led programs at Microsoft that productized the AIML experience for Windows 11 and a Voice Clarity feature launched in 2022 as a premium duplex communication experience for Teams. Prior to Microsoft, he worked as a Senior Director in Siemens Healthineers, driving the development of medical ultrasound devices and solutions in Intracardiac Echocardiography as well as Cardiology and General Imaging, with multiple Class-II and Class-III devices released to the market. Earlier in his career, Wei worked for GE and GE Healthcare, spearheading the development and release of the first e4D curved matrix array for Voluson E10 OB/GYN imaging system that enabled early fetal heart diagnosis.

    Wei earned both his PhD in Engineering Science and Mechanics and MS in Electrical Engineering from Penn State University, and his BS in Mechanical Engineering from Tsinghua University in Beijing, China. He also holds an MBA from the University of Maryland.

  • Bernhard

    Weigl

    Senior Director, Diagnostics Research & Development

    Bernhard

    Weigl

    Senior Director, Diagnostics Research & Development

    As Senior Director of Diagnostics Research and Development at GH Labs, Bernhard H. Weigl leads work to develop the next generation of highly sensitive diagnostic assays for diseases of relevance in LMICs, including TB, cervical cancer, malaria, and more recently, COVID-19. He also oversees the development of global health diagnostic technology R&D, including ultra-sensitive strip-based immunoassays, molecular assays in cartridge and digital formats, novel assay formats, and other biotechnology research.

    Previously, Bernhard led the PATH Diagnostics Group, where he oversaw global health diagnostics programs funded by a variety of sources such as NIAID and NIBIB, the Grand Challenges program of the Bill & Melinda Gates Foundation, USAID, and the PATH Health Innovation Portfolio. He also served as Portfolio Leader for Non-Communicable Disease Diagnostics and as Director of the National Institutes of Health-funded Center for Point-of-Care Diagnostics for Global Health. Prior to that, he was a scientific cofounder at the University of Washington and at Micronics, Inc., where he led teams that developed both instrument-based and stand-alone microfluidic medical diagnostic disposables (including the ABORhCard®, the first FDA-approved instrument-free microfluidic test). Bernhard is also an Affiliate Professor at the University of Washington, Department of Bioengineering.

    Bernhard holds a Ph.D. and M.Sc from Karl-Franzens-University Graz. He completed post-doctoral studies at the University of Southampton and the University of Washington.